Immune Deficiency Clinical Trial
— COV-POPARTOfficial title:
Covid-19 Vaccine Cohort in Specific Populations
Verified date | January 2022 |
Source | ANRS, Emerging Infectious Diseases |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Multicentre national cohort study with prospective data collection and biological specimen collection. Ancillary study in this cohort : pediatric cohort with participants from 5 to 17 years old. Enrollment complete for adult cohort. Active recruting for ancillary pediatric cohort.
Status | Active, not recruiting |
Enrollment | 6920 |
Est. completion date | June 25, 2024 |
Est. primary completion date | June 25, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | These eligibility criteria only concern the adult cohort. INCLUSION CRITERIA : General inclusion criteria for all patients of all groups - Be 18 years or older - Get vaccinated against Covid-19 as part of the national vaccination campaign or having already received a first or second vaccine injection as part of the national vaccination campaign - Accept the conditions of participation corresponding to each sub-population - Commit to respecting the schedule of visits provided in the research protocol - Plan to reside in France for at least 2.5 years from inclusion date - Give their free, informed and written consent (at the latest on the day of inclusion and before any examination / samples) by signing the consent form - Be a member of or beneficiary of a social security scheme (State Medical Aid is not a social security scheme). General inclusion criteria for patients with a chronic condition of interest - Present at least one pathology listed - If the participant is participating in the in-depth immunology and virology study, they must have only one of the pathology of interest listed Inclusion criteria for control subjects • Be free from the chronic conditions of interest listed or other chronic conditions/treatment that may affect the immune response Inclusion criteria for control subjects free from chronic conditions of interest and with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT162b2 • Be vaccinated with a first injection with Astra-Zeneca vaccine AZD1222 and a second injection with Pfizer ARNm vaccine BNT162b2 NON INCLUSION CRITERIA : General non inclusion Criteria for all participants of all groups - Be under protective supervision (guardian or curatorship) - Being a pregnant or breastfeeding woman - Present a contraindication to Covid-19 vaccination : Have a known or suspected allergy to any component of the vaccine, Have had at-risk contact with a confirmed Covid-19 person in the last 7 days, Have presented clinical signs suggestive of Covid-19 in the last 7 days, Have an acute febrile episode on inclusion / vaccination, Have received a vaccine in the last 15 days ... - Have had a documented Covid-19 Infection (PCR or antigenic test) - Refuse that their Social Security number is collected for accessing the National Health Data System (NSDS)/Data Health Hub national health databases - For safety reasons, must agree to not enter in a vaccine clinical trial during the entire period of inclusion and follow-up of the research Specific non inclusion criteria for PLWHIV - Being infected with HIV-2 - Presenting another cause for immunosuppression (undergoing immunosuppressive treatment, biotherapy) - Presenting a non controlled opportunistic infection Specific non-inclusion criteria for control subjects - Have one or more of the chronic conditions of interest listed or affected by any other pathology or treatment that may affect the immune response (autoimmune/inflammatory pathology or immune deficiency not listed, liver failure, immunosuppressive therapy (like oral corticosteroids at >= 10 mg/d Prednisone equivalent for more than 15 days) or radiotherapy within 6 months prior to inclusion or planned for the duration of the study) - Life expectancy of less than 2 years |
Country | Name | City | State |
---|---|---|---|
France | Cmg-Ec U1219 | Bordeaux | |
France | Nîmes CHU | Nîmes | |
France | Paris Cochin APHP | Paris |
Lead Sponsor | Collaborator |
---|---|
ANRS, Emerging Infectious Diseases | Institut National de la Santé Et de la Recherche Médicale, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | These primary outcome only concern the adult cohort. Humoral immunity to Covid-19 vaccination using 2 serological criteria: | Anti-Spike (test 1) and anti RBD (test 2) antibodies (quantitative Elisa)
Seroneutralization, by conventional in vitro seroneutralization test, for participants having test 1 and / or test 2 positive: percentage of patients with a neutralizing antibody titre specific to SARS-CoV-2 =20. Seroneutralization, by neutralization test on SARS-CoV-2 variants, in the first 50 participants included by subpopulation and with test 1 and / or test 2 positive: SARS-CoV-2 specific neutralizing antibodies titre |
before the second injection (if applicable) | |
Primary | Humoral immunity to Covid-19 vaccination using 2 serological criteria: | Anti-Spike (test 1) and anti RBD (test 2) antibodies (quantitative Elisa)
Seroneutralization, by conventional in vitro seroneutralization test, for participants having test 1 and / or test 2 positive: percentage of patients with a neutralizing antibody titre specific to SARS-CoV-2 =20. Seroneutralization, by neutralization test on SARS-CoV-2 variants, in the first 50 participants included by subpopulation and with test 1 and / or test 2 positive: SARS-CoV-2 specific neutralizing antibodies titre |
Month 1 | |
Primary | Humoral immunity to Covid-19 vaccination using 2 serological criteria: | Anti-Spike (test 1) and anti RBD (test 2) antibodies (quantitative Elisa)
Seroneutralization for participants having test 1 and / or test 2 positive: percentage of patients with a titre =40 Titre of neutralizing antibodies for participants having test 1 positive (with conventionnal in vitro neutralization test and neutralization test on variants of SARS-CoV-2) |
Month 1 after the third dose (if applicable) | |
Primary | Humoral immunity to Covid-19 vaccination using 2 serological criteria: | Anti-Spike (test 1) and anti RBD (test 2) antibodies (quantitative Elisa)
Seroneutralization, by conventional in vitro seroneutralization test, for participants having test 1 and / or test 2 positive: percentage of patients with a neutralizing antibody titre specific to SARS-CoV-2 =20. Seroneutralization, by neutralization test on SARS-CoV-2 variants, in the first 50 participants included by subpopulation and with test 1 and / or test 2 positive: SARS-CoV-2 specific neutralizing antibodies titre |
Month 6 | |
Primary | Humoral immunity to Covid-19 vaccination using 2 serological criteria: | Anti-Spike (test 1) and anti RBD (test 2) antibodies (quantitative Elisa)
Seroneutralization, by conventional in vitro seroneutralization test, for participants having test 1 and / or test 2 positive: percentage of patients with a neutralizing antibody titre specific to SARS-CoV-2 =20. Seroneutralization, by neutralization test on SARS-CoV-2 variants, in the first 50 participants included by subpopulation and with test 1 and / or test 2 positive: SARS-CoV-2 specific neutralizing antibodies titre |
Month 12 | |
Primary | Humoral immunity to Covid-19 vaccination using 2 serological criteria: | Anti-Spike (test 1) and anti RBD (test 2) antibodies (quantitative Elisa)
Seroneutralization, by conventional in vitro seroneutralization test, for participants having test 1 and / or test 2 positive: percentage of patients with a neutralizing antibody titre specific to SARS-CoV-2 =20. Seroneutralization, by neutralization test on SARS-CoV-2 variants, in the first 50 participants included by subpopulation and with test 1 and / or test 2 positive: SARS-CoV-2 specific neutralizing antibodies titre |
Month 24 | |
Primary | Percentage of participants seroconverting for Anti Nucleoprotein antibodies | (qualitative Elisa) | Inclusion | |
Primary | Percentage of participants seroconverting for Anti Nucleoprotein antibodies | (qualitative Elisa) | before the second injection (if applicable) | |
Primary | Percentage of participants seroconverting for Anti Nucleoprotein antibodies | (qualitative Elisa) | Month 1 | |
Primary | Percentage of participants seroconverting for Anti Nucleoprotein antibodies | (qualitative Elisa) | Month 6 | |
Primary | Percentage of participants seroconverting for Anti Nucleoprotein antibodies | (qualitative Elisa) | Month 12 | |
Primary | Percentage of participants seroconverting for Anti Nucleoprotein antibodies | (qualitative Elisa) | Month 24 | |
Primary | Seroconversion or increase of factor 2 titer of antibodies anti-Spike/anti-RBD between the second and the third dose for the participants with 3 injections | (qualitative Elisa) | Month 1 after the third dose | |
Primary | Seroconversion or increased levels of anti-Spike/anti-RBD antibodies between the last injection of the initial vaccine regimen and the booster dose | (qualitative Elisa) | Month 1 after the booster dose | |
Secondary | These secondary outcome only concern the adult cohort. Cellular immunity to Covid-19 vaccination | ELISpot Test | Inclusion | |
Secondary | Cellular immunity to Covid-19 vaccination | ELISpot Test | Month 6 | |
Secondary | Cellular immunity to Covid-19 vaccination | ELISpot Test | Month 24 | |
Secondary | For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : humoral and cellular immunity to Covid-19 vaccination | qualitative Elisa and ELISpot Test | Inclusion | |
Secondary | For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : humoral and cellular immunity to Covid-19 vaccination | qualitative Elisa and ELISpot Test | Month 1 | |
Secondary | For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : collection of immediate adverse effects | collection by a self-monitoring log | within 15 minutes after injection of Pfizer ARNm vaccine | |
Secondary | For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : collection of adverse effects expected from the database | collection by a self-monitoring log | within 7 days after injection of Pfizer ARNm vaccine | |
Secondary | For participants with first injection with Astra-Zeneca vaccine AZD1222 and second injection with Pfizer ARNm vaccine BNT161b2 : collection of adverse effects | collection by a self-monitoring log | within 28 days after injection of Pfizer ARNm vaccine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00527878 -
Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome
|
Phase 2 | |
Completed |
NCT04643639 -
Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis
|
Phase 3 | |
Completed |
NCT05256784 -
Mountain Food and Natural Probiotic in Nutrition
|
||
Recruiting |
NCT04448951 -
Immune Homeostasis in Sepsis and Septic Shock
|
||
Recruiting |
NCT03721146 -
ENCAPSID Study : ENCApsulated Bacterial Infection and Primary, Secondary ImmunoDeficiency
|
||
Not yet recruiting |
NCT06089174 -
Assessment of the Increased Risk of Infection Following an Ultratrail
|
N/A | |
Completed |
NCT02895204 -
Effect of Fermented Maillard Reacted Whey Protein on Immune Function
|
N/A | |
Recruiting |
NCT03707782 -
Mechanisms of Immune Deficiency
|
||
Recruiting |
NCT06332196 -
Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric Lymphomas
|
N/A | |
Recruiting |
NCT04646525 -
The Relationship Between Covid-19 Infection in Pediatric Patients and Secondary Lymphoid Organs
|
||
Active, not recruiting |
NCT00852943 -
Screening Protocol for Genetic Diseases of Allergic Inflammation
|
||
Completed |
NCT03609840 -
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
Not yet recruiting |
NCT01359384 -
Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment
|
N/A | |
Recruiting |
NCT05605808 -
Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving Chemotherapy
|
N/A | |
Completed |
NCT03899480 -
Adoptive Transfer of Haploidentical NK Cells and N-803
|
Phase 1 | |
Completed |
NCT03051425 -
Immune Benefits of Consumption of Dairy Yogurt in Elderly
|
N/A | |
Enrolling by invitation |
NCT04382508 -
Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.
|
||
Completed |
NCT02334943 -
Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment
|
N/A | |
Completed |
NCT03052491 -
Effects of a 10 Component Dietary Supplement on Health and the Quality of Life
|
N/A | |
Completed |
NCT03881566 -
Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients
|